Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 7/20 | 0.38 |
| ▸ | LCK | P06239 | 4/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 2/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792558 | 0.96 | PROKR1 (0.37) | PTK6LCKAURKBPROKR1RBP4 | |
| SCHEMBL3792576 | 0.94 | PTK6 (0.37) | PTK6LCKAURKBPROKR1RBP4 | |
| SCHEMBL3786082 | 0.91 | PTK6 (0.36) | PTK6LCKAURKBPROKR1RBP4 | |
| SCHEMBL3797171 | 0.90 | AKT1 (0.40) | PTK6LCKAURKBPROKR1RBP4 | |
| SCHEMBL3793467 | 0.89 | LIPG (0.37) | PTK6LCKAURKBPROKR1PIK3CD | |
| SCHEMBL3792637 | 0.85 | PROKR1 (0.39) | PTK6LCKAURKBPROKR1PIK3CD | |
| SCHEMBL13228542 | 0.84 | PIK3CD (0.38) | PROKR1RBP4PIK3CD | |
| SCHEMBL3064044 | 0.84 | PROKR1 (0.34) | PTK6LCKAURKBPROKR1RBP4 | |
| SCHEMBL3063347 | 0.83 | PROKR1 (0.35) | PTK6LCKAURKBPROKR1RBP4 | |
| SCHEMBL3696844 | 0.83 | PROKR1 (0.36) | PTK6LCKAURKBPROKR1KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | claimed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | PTK6 4396/4885LCK 2497/4885AURKB 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.